Treatment Goals in Schizophrenia: A Real-World Survey of Patients, Psychiatrists, and Caregivers in the United States, with an Analysis of Current Treatment (Long-Acting Injectable vs Oral Antipsychotics) and Goal Selection
Heather M Fitzgerald,1 Jason Shepherd,2 Hollie Bailey,2 Mia Berry,2 Jack Wright,2 Maxine Chen3 1Lundbeck LLC, Deerfield, IL, USA; 2Adelphi Real World, Bollington, UK; 3Otsuka Pharmaceutical & Commercial Development, Inc., Princeton, NJ, USACorrespondence: Maxine ChenOtsuka Pharmaceutical & C...
Guardado en:
Autores principales: | Fitzgerald HM, Shepherd J, Bailey H, Berry M, Wright J, Chen M |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/964c22818f9941159df09b9df3e97282 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Targets, attitudes, and goals of psychiatrists treating patients with schizophrenia: key outcome drivers, role of quality of life, and place of long-acting antipsychotics
por: de Bartolomeis A, et al.
Publicado: (2016) -
Taiwan Expert Consensus Recommendations for Switching to Aripiprazole Long-Acting Once-Monthly in Patients with Schizophrenia
por: Chih-Sung Liang, et al.
Publicado: (2021) -
Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life
por: Montemagni C, et al.
Publicado: (2016) -
Gender Differences in the First-Year Antipsychotic Treatment for Chinese First-Episode Schizophrenia
por: Pu C, et al.
Publicado: (2020) -
Attitudes toward long-acting injectable antipsychotics among patients with schizophrenia in Japan
por: Sugawara N, et al.
Publicado: (2019)